Open Trials

At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  With collaborations with Sarah Cannon Research Institute (SCRI) and VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.

BREAST CANCER - NEOADJUVANT

USOR 22-297: Phase 3, open-label, randomized study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab with or without chemotherapy versus neoadjuvant pembrolizumab pulse chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy for the treatment of adult patients with previously untreated triple-negative or hormone receptor-low/HER2-negative breast cancer (D926QC00001). Click here to learn more

BREAST CANCER - ADJUVANT

USOR 22-326: Phase 3, open-label, randomized study to assess the efficacy and safety of camizestrant (AZD9833, a next-generation, oral selective estrogen receptor degrader) vs standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease (CAMBRIA-2). Click here to learn more

LUNG

USOR 23-235: Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer. Click here to learn more

PREVENTION

URCC 19185: Multicenter, randomized trial comparing Brief Behavioral Therapy for Cancer-Related Insomnia (BBT-CI) vs. Healthy Eating Education Learning (HEAL) for treatment of insomnia. Click here to learn more

URCC 22063: Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia. Click here to learn more